Expression of semaphorin 3c in breast cancer and its impact on adhesion and invasion of breast cancer cells

Anticancer Research

Volumn 36, Issue 3, 2016, Pages 1281-1286

  Malik, Muhammad Faraz Arshad ^a,b   Satherley, Lucy K ^a   Davies, Eleri L ^c   Ye, Lin ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b COMSATS Institute of Information Technology ^*  (Pakistan)

^c LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Differentiation; Semaphorin 3C

Indexed keywords

ESTROGEN RECEPTOR; SEMAPHORIN; SEMAPHORIN 3C; UNCLASSIFIED DRUG; HAMMERHEAD RIBOZYME; MESSENGER RNA; RIBOZYME; SEMA3C PROTEIN, HUMAN;

ARTICLE; BREAST; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL ASSAY; CELL FUNCTION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; MDA MB 231 CELL LINE; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SEMA3C GENE; TRANSGENE; TUMOR INVASION; BREAST TUMOR; CANCER STAGING; CELL DIFFERENTIATION; CELL MOTION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MCF-7 CELLS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RNA, CATALYTIC; RNA, MESSENGER; SEMAPHORINS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84991585671     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
2. Luo Y, Raible D and Raper JA: Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75: 217-227, 1993.
3. Kumanogoh A and Kikutani H: Roles of the semaphorin family in immune regulation. Adv Immunol 81: 173-198, 2003.
4. Malik MF, Ye L and Jiang WG: The Plexin-B family and its role in cancer progression. Histol Histopathol 29: 151-165, 2014.
5. Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF and Minna JD: Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21. 3 candidate tumor-suppressor gene SEMA3B. Proc Natl Acad Sci USA 98: 13954-13959, 2001.
6. Nasarre P, Constantin B, Rouhaud L, Harnois T, Raymond G, Drabkin HA, Bourmeyster N and Roche J: Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia 5: 83-92, 2003.
7. Yacoub M, Coulon A, Celhay O, Irani J, Cussenot O and Fromont G: Differential expression of the semaphorin 3A pathway in prostatic cancer. Histopathology 55: 392-398, 2009.
8. Herman JG and Meadows GG: Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. Int J Oncol 30: 1231-1238, 2007.
9. Martin-Satue M and Blanco J: Identification of semaphorin E gene expression in metastatic human lung adenocarcinoma cells by mRNA differential display. J Surg Oncol 72: 18-23, 1999.
10. Osada R, Horiuchi A, Kikuchi N, Ohira S, Ota M, Katsuyama Y and Konishi I: Expression of semaphorins, vascular endothelial growth factor and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 37: 1414-1425, 2006.
11. Muller MW, Giese NA, Swiercz JM, Ceyhan GO, Esposito I, Hinz U, Buchler P, Giese T, Buchler MW, Offermanns S and Friess H: Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int J Cancer 121: 2421-2433, 2007.
12. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K and Mansel RE: Differential expression of the CCN family members CYR61, CTGF and NOV in human breast cancer. Endocr Relat Cancer 11: 781-791, 2004.
13. Jiang WG, Grimshaw D, Lane J, Martin TA, Abounader R, Laterra J and Mansel RE: A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 7: 2555-2562, 2001.
14. Malik FA, Sanders AJ, Jones AD, Mansel RE and Jiang WG: Transcriptional and translational modulation of KAI1 expression in ductal carcinoma of the breast and the prognostic significance. Int J Mol Med 23: 273-278, 2009.
15. Miyato H, Tsuno NH and Kitayama J: Semaphorin 3C is involved in the progression of gastric cancer. Cancer Sci 103: 1961-1966, 2012.
16. Joseph D, Ho SM and Syed V: Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer. Mol Cancer Ther 9: 499-509, 2010.
17. Sorbello V, Fuso L, Sfiligoi C, Scafoglio C, Ponzone R, Biglia N, Weisz A, Sismondi P and De Bortoli M: Quantitative realtime RT-PCR analysis of eight novel estrogen-regulated genes in breast cancer. Int J Biol Markers 18: 123-129, 2003.
18. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, Zammataro L, Primo L, Tamagnone L, Logan M, Tessier-Lavigne M, Taniguchi M, Puschel AW and Bussolino F: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424: 391-397, 2003.
19. Gu C, Limberg BJ, Whitaker GB, Perman B, Leahy DJ, Rosenbaum JS, Ginty DD and Kolodkin AL: Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem 277: 18069-18076, 2002.
20. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O and Neufeld G: Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 282: 26294-26305, 2007.
21. Blanc V, Nariculam J, Munson P, Freeman A, Klocker H, Masters J and Williamson M: A role for class 3 semaphorins in prostate cancer. Prostate 71: 649-658, 2011.
22. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D and Roche J: Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 7: 180-189, 2005.
23. Castro-Rivera E, Ran S, Thorpe P and Minna JD: Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA 101: 11432-11437, 2004.
24. Jiang H, Qi L, Wang F, Sun Z, Huang Z and Xi Q: Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma. Int J Mol Med 35: 1374-1380, 2015.
25. Tseng CH, Murray KD, Jou MF, Hsu SM, Cheng HJ and Huang PH: Sema3E/plexin-D1 mediated epithelial-to-mesenchymal transition in ovarian endometrioid cancer. PLoS One 6: e19396, 2011.
26. Drenberg CD, Livingston S, Chen R, Kruk PA and Nicosia SV: Expression of semaphorin 3F and its receptors in epithelial ovarian cancer, fallopian tubes and secondary Mullerian tissues. Obstet Gynecol Int 16: 730-739, 2009.